Home | Meeting coverage | ASH 2021

DLBCL Discussions: ASH 2021 – ENG

ASH 2021

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

Part II: CAR-T cells - all over the field data for...

ZUMA-7, TRANSFORM, Belinda

ASH 2021

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

Part I: Pola-R-CHP - possible new standard in 1st line?

POLARIX

DLBCL – ENG

ASH 2021

Martin Dreyling, MD

axi-cel, tisa-cel, liso-cel: New CAR-T options for R/R...

ZUMA-7, BELINDA, TRANSFORM

ASH 2021

Mats Jerkeman, MD

Tisa-cel - new CAR-T option for R/R aNHL

BELINDA

ASH 2021

Marco Ladetto, MD

Prevention of CNS relapse after R-CHOP

ASH 2021

Mats Jerkeman, MD

HD-MTX does not lower SCNS rates in high-risk patients

ASH 2021

Martin Dreyling, MD

pola-R-CHP vs. R-CHOP: a new standard?

POLARIX

ASH 2021

Marco Ladetto, MD

Axi-cel - new standard for r/r LBCL patients?

ZUMA‑7

DLBCL – GER/ITA

ASH 2021

Marco Ladetto, MD

Axi Cel: un nuovo standard nel DLBCL recidivato o...

ZUMA‑7

ASH 2021

Martin Dreyling, MD

pola-R-CHP vs. R-CHOP: Neuer Standard?

POLARIX

ASH 2021

Marco Ladetto, MD

La prevenzione della recidiva a carico del sistema...

ASH 2021

Martin Dreyling, MD

Axi-Cel I Tisa-Cel I Liso-Cel: Drei neue CAR-T-Optionen...

ZUMA-7, BELINDA, TRANSFORM

Mantle Cell Lymphoma Discussions: ASH 2021 – ENG

ASH 2021

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

Part II: The white elephant in the room - BTKi

BRUIN

ASH 2021

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

Part I: Potential change in first-line treatment?

MCL R2 Elderly

Mantle Cell Lymphoma – ENG

ASH 2021

Ana Marín Niebla, MD, PhD

Encouraging real world safety and efficacy data of...

ASH 2021

Martin Dreyling, MD

Next generation BTKI Pirtobrutinib

BRUIN

ASH 2021

Toby A. Eyre, MD

Pirtobrutinib - promising agent moving forward

BRUIN

ASH 2021

Ana Marín Niebla, MD, PhD

Low-dose lenalidomide added to rituximab maintenance in...

MCL R2 Elderly

ASH 2021

Mats Jerkeman, MD

Glofitamab SUD as monotherapy after Gpt induced high...

ASH 2021

Ana Marín Niebla, MD PhD

HiDAC-containing induction before ASCT substantially...

MCL Younger

ASH 2021

Martin Dreyling, MD

Maintenance with Rituximab-Lenalidomid (R2)

MCL R2 Elderly

ASH 2021

Ana Marín Niebla, MD PhD

Pirtobrutinib shows promising efficacy and safety in...

BRUIN, BRUIN MCL-321

ASH 2021

Marco Ladetto, MD

Focus on maintenance is critical in MCL

MCL R2 Elderly

Mantle Cell Lymphoma – GER/ITA/ESP

ASH 2021

Ana Marín Niebla, MD PhD

La inducción con citarabina a dosis altas antes del...

MCL Younger

ASH 2021

Martin Dreyling, MD

Rituximab-Lenalidomid Erhaltungstherapie (R2)

MCL R2 Elderly

ASH 2021

Ana Marín Niebla, MD PhD

Añadir lenalidomida a dosis bajas a rituximab en el...

MCL R2 Elderly

ASH 2021

Ana Marín Niebla, MD PhD

Pirtobrutinib es eficaz y seguro en pacientes muy...

BRUIN, BRUIN MCL-321

ASH 2021

Marco Ladetto, MD

Ruolo del mantenimento con R2 nel linfoma mantellare

MCL R2 Elderly

ASH 2021

Ana Marín Niebla, MD PhD

Eficacia y seguridad de brexu-cel en pacientes con LCM...

ASH 2021

Martin Dreyling, MD

Pirtobrutinib: Neuer, nicht-kovalenter BTKi

BRUIN

Follicular Lymphoma Discussions: ASH 2021 – ENG

ASH 2021

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

Part II: Bi-specific antibodies as an attractive agent

ASH 2021

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

Part I: CAR-T cells on the way

ZUMA-5, ELARA

Follicular Lymphoma – ENG

ASH 2021

Martin Dreyling, MD

Novel immunotherapy approaches to R/R follicular...

ASH 2021

Toby A. Eyre, MD

Active new therapy for 3L+ R/R FL

ASH 2021

Martin Dreyling, MD

First-line options and RM

FOLL12

ASH 2021

Marco Ladetto, MD

MRD monitoring in follicular lymphoma is extremely...

FOLL12

Follicular Lymphoma – GER/ITA

ASH 2021

Marco Ladetto, MD

Ruolo del monitoraggio della malattia minima residua...

FOLL12

ASH 2021

Martin Dreyling, MD

Mosunetuzumab + Lenalidomid beim r/r FL

ASH 2021

Martin Dreyling, MD

Rituximab-Erhaltung nach ICT bleibt Standard

FOLL12

Chronic/Small Lymphocytic Leukemia Discussions: ASH 2021 – ENG

ASH 2021

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Ladetto, T. Eyre

Part II: More data to wait for

CLL13 / GAIA, FLAIR

ASH 2021

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

Part I: Promising data in CLL

BRUIN CLL, SEQUOIA

Chronic/Small Lymphocytic Leukemia – ENG

ASH 2021

Toby A. Eyre, MD

BTKi as new option for untreated CLL/SLL patients

SEQUOIA

ASH 2021

Toby A. Eyre, MD

Pirtobrutinib - promising efficacy in heavily...

BRUIN

Multiple Myeloma Discussions - ENG

ASH 2021

H. Einsele, P. Sonneveld, B. C. Lipe, F. H. Schjesvold, M. Merz

The immunotherapy tsunami continues - bispecific...

MajesTEC-1, TRIMM-2, Magnetismm-1, MonumenTAL-1

ASH 2021

F. H. Schjesvold, M. Merz, C. O. Landgren, H. Einsele, P. Sonneveld, B. C. Lipe

Big data on smoldering multiple myeloma: the iStopMM...

iStopMM

ASH 2021

H. Einsele, P. Sonneveld, B. C. Lipe, F. H. Schjesvold, M. Merz

The immunotherapy tsunami continues - CAR-T cells

CARTITUDE-1, CARTITUDE-2

ASH 2021

F. H. Schjesvold, M. Merz, C. O. Landgren, H. Einsele, P. Sonneveld, B. C. Lipe

NDMM: On the way to cure?

CASSIOPEIA, Griffin, GMMG-HD7, HOVON 143, etc.

Newly Diagnosed Multiple Myeloma – ENG

ASH 2021

C. Ola Landgren, MD PhD

The future is already here - the use of antibodies in...

Griffin; CASSIOPEIA; MANHATTAN

ASH 2021

Maximilian Merz, MD

Positive results for high-risk myeloma from the UK

Muknine

ASH 2021

Pieter Sonneveld, MD

Quadruple regimens for NDMM

GMMG-HD7

ASH 2021

Hermann Einsele, MD

Quadruple therapy - the treatment of choice in NDMM

CASSIOPEIA, Griffin

ASH 2021

Maximilian Merz, MD

No benefit for elotuzumab in NDMM

GMMG-HD6 Trial

ASH 2021

Fredrik Hellem Schjesvold, MD PhD

PFS separation in the Griffin trial

Griffin

ASH 2021

Pieter Sonneveld, MD

Triplet therapie in elderly patients

HOVON 143

Newly Diagnosed Multiple Myeloma – GER/NOR/SWE

ASH 2021

C. Ola Landgren, MD, PhD

The future is already here - the use of antibodies in...

Griffin, CASSIOPEIA, MANHATTAN

ASH 2021

Hermann Einsele, MD

Quadrupletts Dara-VTd bzw. Dara-RCd erste Optionen bei...

CASSIOPEIA, Griffin

ASH 2021

Maximilian Merz, MD

Isatuximab + RVd erfogreich, Elotuzumab nicht

GMMG-HD6 Trial, GMMG-HD7 Trial

ASH 2021

Fredrik Hellem Schjesvold, MD PhD

PFS separation in the Griffin trial

Griffin

Relapsed/Refractory Multiple Myeloma – ENG

ASH 2021

Brea C. Lipe, MD

Personalized medicine with venetoclax

BELLINI

ASH 2021

C. Ola Landgren, MD PhD

New bispecific antibodies and CAR-T cells for RRMM...

MajesTEC-1; Magnetismm-1; CARTITUDE-1

ASH 2021

Hermann Einsele, MD

talquetamab & cevostamab: bispecific antibodies beyond...

MonumenTAL-1, TRIMM-2

ASH 2021

Fredrik Hellem Schjesvold, MD PhD

TAK-573 - a really new mechanism of treatment in...

ASH 2021

Brea C. Lipe, MD

Not another BCMA drug

MonumenTAL-1

ASH 2021

Pieter Sonneveld, MD

Is CAR-T cell treatment better in heavly pretreated...

CARTITUDE-1

ASH 2021

Fredrik Hellem Schjesvold, MD PhD

KRd consolidation reverses PET positivity in 1/3 of the...

CONPET

ASH 2021

Katja Weisel, MD

Update on bispecific antibody teclistamab

MajesTEC-1

ASH 2021

Katja Weisel, MD

cilta-cel highly effective in heavily pretreated...

CARTITUDE-1

ASH 2021

Hermann Einsele, MD

cilta-cel: early, deep and durable responses in heavily...

CARTITUDE-1

ASH 2021

Maximilian Merz, MD

Elranatamab - a new bispecific antibody in RRMM

Magnetismm-1

Relapsed/Refractory Multiple Myeloma – GER/NOR/SWE

ASH 2021

Katja Weisel, MD

cilta-cel hoch erfolgreich bei stark vorbehandelten...

CARTITUDE-1

ASH 2021

Hermann Einsele, MD

cilta-cel: frühes, tiefes, lang anhaltendes Ansprechen...

CARTITUDE-1

ASH 2021

Maximilian Merz, MD

CAR-T oder bispezifische MoAk in der Rezidivtherapie -...

MonumenTAL-1, Magnetismm-3

ASH 2021

C. Ola Landgren, MD, PhD

New bispecific antibodies and CAR-T cells for RRMM...

MajesTEC-1, Magnetismm-1, CARTITUDE-1

ASH 2021

Fredrik Hellem Schjesvold, MD PhD

TAK-573 - a really new mechanism of treatment in...

ASH 2021

Fredrik Hellem Schjesvold, MD PhD

KRd consolidation reverses PET-positivity in 1/3 of the...

CONPET

ASH 2021

Hermann Einsele, MD

Talquetamab und Cevostamab: Neue bispezifische Ak...

MonumenTAL-1, TRIMM-2

ASH 2021

Katja Weisel, MD

Bispezifischer Antikörper Teclistamab beim r/r MM

MajesTEC-1

Smoldering Myeloma / MGUS – ENG

ASH 2021

Fredrik Hellem Schjesvold, MD PhD

New reference values for light chains in multiple...

iStopMM

ASH 2021

C. Ola Landgren, MD PhD

Myeloma precursor disease 2021

iStopMM

ASH 2021

Brea C. Lipe, MD

MGUS and COVID-19 risk

iStopMM

Smoldering Myeloma / MGUS – NOR/SWE/GER

ASH 2021

C. Ola Landgren, MD, PhD

Myeloma precurser disease 2021

iStopMM

ASH 2021

Fredrik Hellem Schjesvold, MD PhD

New reference values for light chains in multiple...

iStopMM

ASH 2021

Maximilian Merz, MD

Prävalenz und Risikostratifikation beim SMM

iStopMM, PROMISE